List of Excipients in Branded Drug METHYLTESTOSTERONE

« Back to Dashboard

Generic Drugs Containing METHYLTESTOSTERONE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	methyltestosterone	0115-1408	D&C YELLOW NO. 10
Amneal Pharmaceuticals of New York LLC	methyltestosterone	0115-1408	FD&C BLUE NO. 1
Amneal Pharmaceuticals of New York LLC	methyltestosterone	0115-1408	FD&C BLUE NO. 2
Amneal Pharmaceuticals of New York LLC	methyltestosterone	0115-1408	FD&C RED NO. 40
Amneal Pharmaceuticals of New York LLC	methyltestosterone	0115-1408	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in METHYLTESTOSTERONE?

# Of NDCs	Excipient
1	AMMONIA
1	ANHYDROUS LACTOSE
2	D&C YELLOW NO. 10
2	FD&C BLUE NO. 1
1	FD&C BLUE NO. 2

Methyltestosterone Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Methyltestosterone is an established oral androgen with limited modern U.S. commercial presence, no meaningful remaining composition-of-matter exclusivity, and a product profile shaped more by regulatory, safety, and manufacturing constraints than by patent barriers. The strongest commercial opportunities are differentiated low-dose oral formulations, specialty-market products, and combination products supported by new formulation or method-of-use claims.

The commercial case is constrained by hepatic safety concerns, androgenic adverse effects, controlled-substance requirements, limited clinical demand, and competition from testosterone replacement products with more established delivery systems. Excipient selection should prioritize dose uniformity, chemical stability, dissolution, taste control for sublingual products, and compatibility with low-dose manufacturing.

What is methyltestosterone and how is it administered?

Methyltestosterone is a synthetic 17-alpha-alkylated androgen administered orally. The molecule is structurally related to testosterone but has a methyl group at the 17-alpha position, which supports oral activity and also contributes to hepatic risk.

Historically marketed dosage forms include:

Product type	Typical strength or use	Commercial relevance
Oral tablets	10 mg and 25 mg	Primary legacy dosage form
Sublingual tablets	10 mg and 25 mg	Designed for rapid mucosal absorption
Combination tablets	Methyltestosterone with esterified estrogens	Historical menopausal symptom product
Compounded capsules or troches	Variable	Specialty and compounding-market opportunity
Investigational modified-release products	Not established commercially	Potential formulation-development pathway

U.S. labeling has included treatment of androgen deficiency in males and selected androgen-responsive conditions. Historical labeling also covered female indications in limited circumstances, although contemporary use is narrower because of safety and availability considerations.[1]

Methyltestosterone is subject to controlled-substance regulation as an anabolic steroid under Schedule III of the U.S. Controlled Substances Act.[2]

What FDA regulatory status applies to methyltestosterone?

FDA regulatory status depends on the specific product, sponsor, dosage form, and marketing history. Methyltestosterone has been approved historically in oral products, but several branded products and combination products have been discontinued or are no longer actively marketed.

FDA’s Orange Book distinguishes between approved products and products that have been discontinued from commercial distribution. A discontinued listing does not automatically mean that the product’s approval was withdrawn for safety or efficacy reasons.[3]

FDA status and regulatory considerations

Regulatory issue	Methyltestosterone implication
Active ingredient	Established synthetic androgen
Regulatory pathway	Abbreviated New Drug Application may be possible for an eligible reference product
Controlled substance	Schedule III requirements apply
Prescription status	Prescription-only product
Clinical safety	Hepatic, cardiovascular, prostate, virilization, and lipid-related risks
Manufacturing	Controlled-substance inventory, security, recordkeeping, and diversion controls
New dosage form	May require a 505(b)(2) application or full NDA, depending on the product and reference framework
Combination product	May require new clinical and labeling support if the proposed use differs materially from historical products

The most commercially relevant regulatory question is whether an applicant can identify a currently suitable reference listed drug and establish pharmaceutical equivalence. If no active reference product supports a conventional ANDA, a 505(b)(2) strategy may be more practical for a new dosage form, route, strength, or combination.

When does methyltestosterone lose exclusivity?

Methyltestosterone lost practical composition-of-matter exclusivity decades ago. Its remaining commercial protection would arise from product-specific formulation, method-of-use, regulatory, or manufacturing patents rather than from the active ingredient.

Exclusivity categories

Exclusivity type	Current commercial significance
Composition-of-matter patent	Expired
Basic oral formulation patent	Likely expired or commercially irrelevant
Historical product patents	Generally expired
New formulation patent	Possible for a differentiated product
Method-of-use patent	Possible but difficult to enforce without a narrow, clinically supported indication
Orphan-drug exclusivity	No established current basis for methyltestosterone
New chemical entity exclusivity	Unavailable
Pediatric exclusivity	No established current protection
Controlled-substance status	Regulatory obligation, not market exclusivity

A sponsor developing a new product should not assume that historical branded methyltestosterone products provide an active patent barrier. The relevant clearance exercise should focus on current patents associated with the specific reference product, formulation, manufacturing process, and proposed indication.

What patents protect methyltestosterone products?

No broad, commercially meaningful active-ingredient patent protection is expected for methyltestosterone. The principal opportunity is to obtain narrow patents around formulation performance or a specific therapeutic use.

Potential patent categories include:

1. Sublingual or buccal dosage forms with defined disintegration or absorption characteristics.
2. Taste-masked oral formulations.
3. Solid dispersions or lipid-based systems that improve dissolution.
4. Modified-release tablets that reduce peak plasma concentrations.
5. Low-dose formulations with improved content uniformity.
6. Stabilized formulations that limit oxidation or degradation.
7. Combination products containing methyltestosterone and another hormone.
8. Manufacturing processes that improve blend uniformity or reduce handling losses.
9. Patient-specific dosing regimens supported by clinical data.
10. Packaging systems that limit light, oxygen, or moisture exposure.

A patent covering only the use of conventional excipients with methyltestosterone would face a higher validity risk unless it demonstrates an unexpected technical effect. Stronger claims would connect the excipient system to measurable performance, such as improved stability, reduced variability, faster sublingual absorption, lower impurity formation, or a clinically relevant pharmacokinetic profile.

What excipients are suitable for methyltestosterone tablets?

Methyltestosterone is a low-dose, poorly water-soluble steroidal compound. The excipient strategy should address content uniformity, dissolution, tablet robustness, chemical stability, and patient acceptability.

Direct-compression tablet strategy

A conventional immediate-release tablet could use:

Function	Candidate excipient classes	Development rationale
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Supports tablet mass and dose uniformity
Binder	Povidone, copovidone, low-substituted hydroxypropyl cellulose	Improves granule or tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid disintegration
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Taste modifier	Sucralose, saccharin sodium, flavor systems	Relevant to chewable or sublingual products
Film coat	Hypromellose, polyvinyl alcohol, polyethylene glycol	Supports appearance and handling

Low-dose steroid products require particular attention to segregation and blend uniformity. Direct compression may be suitable if the active ingredient has adequate flow and particle-size control. Otherwise, geometric dilution, ordered mixing, dry granulation, or spray-dried intermediate materials may be needed.

Excipient risks

Several formulation risks require early screening:

• Magnesium stearate can slow dissolution if over-lubrication occurs.
• Hydrophobic excipients may reduce wetting and dissolution.
• Lactose may create compatibility concerns if impurities or degradation pathways are present.
• Excessive binder levels may delay disintegration.
• High-surface-area silica can alter powder flow and active distribution.
• Polyols and sweeteners can affect moisture uptake in sublingual products.
• Flavoring agents may create stability or regulatory issues.

The target product profile should specify assay uniformity, dissolution across relevant pH conditions, degradation products, tablet friability, hardness, and in-use stability.

What formulations are protected by methyltestosterone patents?

A new formulation is more likely to produce defensible intellectual property if it solves a documented technical problem. The strongest candidates are not simply new excipient lists. They are formulations tied to a measurable product advantage.

Sublingual formulations

Sublingual methyltestosterone products can be designed around:

• Rapid wetting and disintegration.
• Controlled tablet erosion.
• Taste masking.
• Reduced swallowing.
• Defined mucosal exposure.
• Reduced reliance on gastrointestinal absorption.

Potential excipients include mannitol, compressible sugars, crospovidone, low-substituted hydroxypropyl cellulose, acesulfame potassium, sucralose, and polymeric taste-masking systems. A patent may be stronger if it claims a defined disintegration time, dissolution profile, particle-size distribution, or pharmacokinetic range.

Modified-release formulations

Modified-release delivery could address peak-related adverse effects or reduce dosing frequency. Candidate technologies include:

• Hydrophilic matrix tablets using hypromellose.
• Multiparticulates with polymeric coatings.
• Osmotic or diffusion-controlled systems.
• Lipid-based systems.
• Layered tablets combining immediate- and extended-release fractions.

The clinical and regulatory burden is higher. A modified-release product would need to demonstrate that altered exposure is therapeutically useful and does not increase androgenic or hepatic risk.

Lipid-based and self-emulsifying systems

A lipid-based formulation may improve dissolution for a poorly soluble steroid. Candidate excipients include medium-chain triglycerides, mono- and diglycerides, polysorbates, and other surfactant systems. These systems can create a differentiated product, but the sponsor must address:

• Excipient tolerability.
• Dose loading.
• Capsule compatibility.
• Oxidative stability.
• Food-effect variability.
• Scale-up and fill-weight control.

Multiparticulate and sprinkle formulations

A sprinkle capsule or oral granule product could target patients with swallowing difficulty. The formulation must protect against segregation, provide uniform dosing, and prevent unintended chewing or crushing if modified release is used.

How strong is the methyltestosterone patent estate?

The legacy patent estate is weak from a blocking-rights perspective because the active ingredient and basic oral dosage forms are old. A new sponsor could obtain formulation patents, but their strength would depend on claim specificity and technical evidence.

Patent dimension	Assessment
Active ingredient protection	Very weak or expired
Basic immediate-release tablet	Weak
Sublingual dosage form	Moderate opportunity if performance is differentiated
Modified release	Moderate opportunity, with higher development risk
Combination product	Moderate opportunity if supported by a distinct indication
Manufacturing process	Moderate if process produces a measurable quality advantage
Method of use	Variable and dependent on clinical support
Freedom to operate against legacy products	Generally favorable, subject to current patent searching
Patent litigation risk	More likely around a new product than around legacy methyltestosterone

A robust patent portfolio would combine composition claims, process claims, and method-of-use claims. The sponsor should avoid relying on a single excipient-combination patent because obviousness challenges may be substantial for an old active ingredient.

What generic entry risks exist for methyltestosterone?

Generic entry risk is high for any conventional immediate-release tablet with an available reference listed drug. The main barriers are commercial rather than technological.

Generic launch scenarios

Scenario	Likely outcome
Conventional 10 mg or 25 mg tablet	High generic substitution risk
Sublingual tablet with defined performance	Moderate risk if formulation claims are enforceable
Modified-release tablet	Lower near-term competition, but higher development cost
Compounded capsule or troche	Fragmented competition rather than classic generic substitution
Combination hormone product	Moderate risk, depending on reference-product status
New indication with method-of-use claims	Risk depends on labeling carve-out and enforcement

A generic applicant could challenge listed patents through Paragraph IV certification if the reference product has active Orange Book-listed patents. For legacy methyltestosterone products, the practical value of Paragraph IV litigation depends on whether an active, marketed reference product and listed patents remain available.

The absence of a meaningful patent estate does not eliminate launch risk. A generic sponsor still faces controlled-substance compliance, limited market size, manufacturing economics, and potential regulatory scrutiny of product quality.

What is the Orange Book status of methyltestosterone?

The Orange Book should be reviewed by product name, active ingredient, dosage form, strength, and application number. Historical products may appear as discontinued, and discontinued status should not be treated as a patent expiration date or a safety withdrawal without reviewing the FDA action code and supporting records.[3]

For commercial planning, the key questions are:

• Is there an active reference listed drug?
• Is the reference product marketed?
• Are patents listed in the Orange Book?
• Is a therapeutic-equivalence code available?
• Does the proposed product match the reference product in route, strength, dosage form, and conditions of use?
• Would a 505(b)(2) application provide a more practical pathway?

A sponsor should treat the Orange Book as a product-specific regulatory database, not as a complete historical patent record.

Which companies are challenging methyltestosterone products?

No major current Paragraph IV litigation campaign is associated with methyltestosterone comparable to the litigation surrounding high-revenue branded drugs. The commercial field is fragmented among legacy manufacturers, generic applicants, specialty pharmacies, and compounders.

The competitive landscape includes:

• Generic drug manufacturers pursuing conventional tablets.
• Specialty manufacturers supplying niche androgen products.
• Compounding pharmacies producing capsules, troches, or customized strengths.
• Developers of alternative testosterone products, including gels, injections, patches, and oral testosterone undecanoate.
• Hormone-therapy companies offering combination products.

The absence of visible litigation reflects the modest market size and age of the molecule, not necessarily the absence of regulatory or product-quality risk.

How does methyltestosterone compare with competing testosterone products?

Methyltestosterone competes against products with different pharmacokinetic and safety profiles.

Product	Route	Main commercial advantage	Main limitation
Methyltestosterone	Oral or sublingual	Low manufacturing complexity and established chemistry	Hepatic risk and limited modern demand
Testosterone gel	Transdermal	Avoids first-pass hepatic exposure	Transfer risk, daily application, variable absorption
Testosterone injection	Intramuscular or subcutaneous	High systemic exposure and established use	Peaks, troughs, injection burden
Testosterone patch	Transdermal	Noninvasive delivery	Skin irritation and adherence
Testosterone undecanoate	Oral or injectable	Oral products can avoid some hepatic first-pass effects through lymphatic absorption	Higher formulation complexity and cost
Buccal testosterone	Mucosal	Local delivery and avoidance of gastrointestinal absorption	Gum irritation and administration constraints

Methyltestosterone may retain a niche where low-cost oral dosing and compact dosage forms are valued. It is less attractive where prescribers prioritize reduced hepatic exposure, stable testosterone levels, or guideline-supported contemporary testosterone replacement options.

What commercial opportunities exist for methyltestosterone?

The most credible opportunities are specialized rather than mass-market.

1. Differentiated sublingual product

A rapidly disintegrating, taste-masked sublingual tablet could target patients who cannot tolerate injections or do not prefer transdermal products. The commercial thesis would require evidence of consistent exposure, acceptable taste, and a clear administration advantage.

2. Low-dose precision product

A low-dose tablet with strong content-uniformity performance could address titration needs in specialty hormone therapy. This opportunity depends on a legally supportable indication and a reliable prescribing channel.

3. Modified-release product

A modified-release product could reduce dosing frequency or smooth exposure. This is the most technically differentiated opportunity but also carries the greatest clinical and regulatory burden.

4. Combination therapy

A fixed-dose combination with another hormone could target a narrow, well-defined condition. The sponsor would need to establish the contribution of each component, justify the ratio, and address historical safety concerns associated with androgen-estrogen combinations.

5. Contract manufacturing and specialty supply

Because methyltestosterone requires controlled-substance handling, smaller companies may prefer an experienced contract development and manufacturing organization. A supplier with validated low-dose blending, containment, and controlled-substance systems could compete through manufacturing reliability rather than patent exclusivity.

6. Ex-U.S. markets

Commercial prospects may exist in countries where methyltestosterone remains registered or where androgen products have different prescribing patterns. Geographic expansion would require country-specific review of:

• National marketing authorizations.
• Controlled-substance schedules.
• Doping and sports restrictions.
• Local patent status.
• Pharmacovigilance requirements.
• Permitted indications and labeling.

U.S. regulatory status cannot be extrapolated directly to Europe, Latin America, Asia, or the Middle East.

What manufacturing and IP barriers affect commercialization?

The main manufacturing barrier is low-dose uniformity. Methyltestosterone must be distributed evenly through the blend, and the process must control segregation during compression, encapsulation, and packaging.

Key manufacturing controls include:

• Particle-size engineering.
• Validated geometric dilution.
• In-process blend sampling.
• Containment and operator protection.
• Controlled-substance inventory reconciliation.
• Cleaning validation.
• Cross-contamination controls.
• Stability testing under heat and humidity.
• Impurity monitoring.
• Child-resistant and tamper-evident packaging where required.

The main IP barrier is the difficulty of obtaining broad claims for a mature compound. New claims should be tied to a narrow technical solution and supported by comparative data against a conventional methyltestosterone formulation.

Key Takeaways

• Methyltestosterone is an old oral androgen with expired composition-of-matter protection.
• The commercial opportunity is formulation-led, not molecule-led.
• Conventional immediate-release tablets face high generic and price competition.
• Sublingual, modified-release, taste-masked, and precision low-dose products offer the strongest differentiation.
• Excipient selection should focus on content uniformity, dissolution, chemical stability, and patient acceptability.
• A new product may require an ANDA, 505(b)(2) application, or NDA depending on the reference-product and indication strategy.
• Controlled-substance compliance is a major operational requirement.
• New patents are more likely to succeed around measurable formulation performance than around broad excipient combinations.
• The largest risks are hepatic safety, limited market size, weak reimbursement leverage, and competition from modern testosterone delivery systems.
• A commercially viable program should combine formulation IP with a narrow, clinically defensible indication and a reliable specialty distribution model.

FAQs

Is methyltestosterone still commercially available?

Availability varies by country, manufacturer, strength, and dosage form. Several historical branded products have been discontinued, while generic, specialty, or compounded supply may remain available in selected markets.

Can methyltestosterone be developed as an ANDA product?

Possibly, if an appropriate reference listed drug is active and the proposed product meets the applicable requirements for pharmaceutical equivalence and bioequivalence. If no suitable marketed reference supports the product, a 505(b)(2) pathway may be more practical.

Which excipient is best for methyltestosterone dissolution?

No single excipient is universally optimal. Wetting agents, hydrophilic diluents, superdisintegrants, and lipid-based systems may improve dissolution, but the final choice must be established through compatibility, dissolution, stability, and bioequivalence studies.

Is a sublingual methyltestosterone product patentable?

Potentially. Patentability would depend on novelty, nonobviousness, and credible technical data showing a meaningful advantage, such as improved disintegration, taste, absorption, stability, or pharmacokinetic performance.

Does methyltestosterone have biosimilar competition?

No. Methyltestosterone is a chemically synthesized small molecule, so competition occurs through generic-drug pathways rather than biosimilar regulation.

References

1. DailyMed. (n.d.). Methyltestosterone tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. Drug Enforcement Administration. (n.d.). Controlled substances act: Schedule III anabolic steroids. U.S. Department of Justice. https://www.dea.gov/drug-information/drug-scheduling

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2022). Guidance for industry: ANDAs for certain highly purified synthetic peptides. https://www.fda.gov/

5. U.S. Food and Drug Administration. (2019). Approved drug product with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-overview

6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.